Magnesium Levels and Heart Problems from Cancer Treatment
Author Information
Author(s): S. Sartori, I. Nielsen, D. Tassinari, A. Maestri, V. Abbasciano
Primary Institution: Arcispedale S.Anna, Università di Ferrara
Hypothesis
Does intracellular magnesium concentration relate to acute anthracycline-induced cardiotoxicity?
Conclusion
The study suggests that lower intracellular magnesium levels may be linked to heart problems caused by anthracycline chemotherapy.
Supporting Evidence
- Patients with reduced magnesium levels had a higher frequency of cardiac disturbances.
- Statistically significant differences were found in the severity of cardiac changes based on magnesium levels.
- All patients received the same dietary regimen to control magnesium intake.
Takeaway
This study looked at how magnesium in the body affects heart health during cancer treatment. It found that patients with lower magnesium levels had more heart issues.
Methodology
Erythrocyte magnesium concentrations were measured before and after doxorubicin or epirubicin administration in cancer patients.
Potential Biases
Potential bias in clinical evaluations as they were conducted by the same physician.
Limitations
The study did not measure myocardial magnesium directly due to ethical concerns.
Participant Demographics
26 cancer patients (5 males and 21 females, aged 46-63 years) without prior heart conditions.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website